Aurinia Pharmaceuticals, Inc.

Is Aurinia Pharmaceuticals, Inc. overvalued or undervalued?

As of October 17, 2025, Aurinia Pharmaceuticals is fairly valued with a P/E ratio of 19 and an EV to EBITDA of 11.23, outperforming the S&P 500 with a 60.86% return over the past year, despite a higher P/E compared to some peers.

As of 17 October 2025, Aurinia Pharmaceuticals, Inc. has moved from a very attractive to a fair valuation grade. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 11.23, and a PEG ratio of 0.10, which suggests that the stock may not be significantly undervalued despite its recent performance.<BR><BR>In comparison with peers, Aurinia's P/E ratio of 20.87 is higher than that of Rhythm Pharmaceuticals, Inc., which has a risky valuation with a P/E of -36.41, indicating a stark contrast in market perception. Additionally, Aurinia's EV to EBITDA ratio is more favorable than that of its peers, reflecting a relatively better valuation position. Notably, over the past year, Aurinia has outperformed the S&P 500, returning 60.86% compared to the index's 14.08%, reinforcing its attractiveness in the market despite a fair valuation.

Is Aurinia Pharmaceuticals, Inc. technically bullish or bearish?

As of October 3, 2025, Aurinia Pharmaceuticals has a mildly bullish trend, with strong short-term performance but underperformance over the past three to five years compared to the S&P 500.

As of 3 October 2025, the technical trend for Aurinia Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are bullish, while the Bollinger Bands show a mildly bullish stance weekly and bullish monthly. Daily moving averages are also mildly bullish. However, the RSI indicates no signal for both weekly and monthly periods, and Dow Theory shows no trend in either timeframe. <BR><BR>In terms of performance, Aurinia has outperformed the S&P 500 on a weekly basis with a return of 2.35% compared to 1.09%, but it has underperformed over the last month with a return of -8.71% versus 4.15%. Year-to-date, Aurinia is up 26.06% compared to the S&P 500's 14.18%, and over the past year, it has significantly outperformed with a return of 58.99% against 17.82%. However, over the longer terms of 3 years and 5 years, it has underperformed relative to the S&P 500. Overall, the current stance is mildly bullish.

How big is Aurinia Pharmaceuticals, Inc.?

As of Jun 18, Aurinia Pharmaceuticals, Inc. has a market capitalization of 1,068.67 million, with net sales of 247.30 million and a net profit of 39.84 million over the latest four quarters. The company reported shareholder's funds of 377.48 million and total assets of 550.64 million as of Dec 24.

Market Cap: As of Jun 18, Aurinia Pharmaceuticals, Inc. has a market capitalization of 1,068.67 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Aurinia Pharmaceuticals reported net sales of 247.30 million and a net profit of 39.84 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 377.48 million and total assets of 550.64 million.

What does Aurinia Pharmaceuticals, Inc. do?

Aurinia Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing therapies for serious diseases. As of March 2025, it reported net sales of $62 million and a net profit of $23 million, with a market cap of approximately $1.07 billion.

Overview:<BR>Aurinia Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies for serious diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 62 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 23 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,068.67 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 19.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.85 <BR>Return on Equity: 16.33% <BR>Price to Book: 3.05 <BR><BR>Contact Details:<BR>Address: 1203-4464 Markham St, VICTORIA BC : V8Z 7X8 <BR>Tel: 1 250 7084272 <BR>Website: https://www.auriniapharma.com

Who are in the management team of Aurinia Pharmaceuticals, Inc.?

As of March 2022, the management team of Aurinia Pharmaceuticals, Inc. is led by Dr. George Milne (Independent Chairman) and Mr. Peter Greenleaf (President and CEO), supported by several directors including Dr. Daniel Billen, Mr. R. Hector MacKay-Dunn, Mr. Joseph Hagan, Dr. Michael Hayden, and Dr. David Jayne.

As of March 2022, the management team of Aurinia Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. George Milne, who serves as the Independent Chairman of the Board.<BR>- Mr. Peter Greenleaf, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Daniel Billen, who is a Director.<BR>- Mr. R. Hector MacKay-Dunn, who is also a Director.<BR>- Mr. Joseph Hagan, serving as an Independent Director.<BR>- Dr. Michael Hayden, who is an Independent Director.<BR>- Dr. David Jayne, who is another Independent Director.<BR><BR>In summary, the management team is led by Dr. George Milne and Mr. Peter Greenleaf, with several directors supporting the leadership.

Should I buy, sell or hold Aurinia Pharmaceuticals, Inc.?